vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and CACI INTERNATIONAL INC (CACI). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $2.2B, roughly 1.3× CACI INTERNATIONAL INC). CACI INTERNATIONAL INC runs the higher net margin — 5.6% vs -3.7%, a 9.3% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 5.7%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $138.2M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs 7.0%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
CACI International Inc is a U.S.-headquartered multinational professional services and information technology firm. It delivers custom technology solutions, cybersecurity services, data analytics, and mission-critical operational support to government defense, intelligence, civilian agencies, and select private sector clients.
BHC vs CACI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $2.2B |
| Net Profit | $-103.0M | $123.9M |
| Gross Margin | — | — |
| Operating Margin | 17.0% | 9.3% |
| Net Margin | -3.7% | 5.6% |
| Revenue YoY | 9.3% | 5.7% |
| Net Profit YoY | -205.1% | 12.7% |
| EPS (diluted) | $-0.30 | $5.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $2.2B | ||
| Q3 25 | $2.7B | $2.3B | ||
| Q2 25 | $2.5B | $2.3B | ||
| Q1 25 | $2.3B | $2.2B | ||
| Q4 24 | $2.6B | $2.1B | ||
| Q3 24 | $2.5B | $2.1B | ||
| Q2 24 | $2.4B | $2.0B | ||
| Q1 24 | $2.2B | $1.9B |
| Q4 25 | $-103.0M | $123.9M | ||
| Q3 25 | $179.0M | $124.8M | ||
| Q2 25 | $148.0M | $157.9M | ||
| Q1 25 | $-58.0M | $111.9M | ||
| Q4 24 | $98.0M | $109.9M | ||
| Q3 24 | $-85.0M | $120.2M | ||
| Q2 24 | $10.0M | $134.7M | ||
| Q1 24 | $-64.0M | $115.3M |
| Q4 25 | 17.0% | 9.3% | ||
| Q3 25 | 23.1% | 9.3% | ||
| Q2 25 | 17.5% | 9.0% | ||
| Q1 25 | 12.2% | 9.1% | ||
| Q4 24 | 21.8% | 8.6% | ||
| Q3 24 | 12.7% | 8.7% | ||
| Q2 24 | 16.2% | 9.7% | ||
| Q1 24 | 13.1% | 9.4% |
| Q4 25 | -3.7% | 5.6% | ||
| Q3 25 | 6.7% | 5.5% | ||
| Q2 25 | 5.8% | 6.9% | ||
| Q1 25 | -2.6% | 5.2% | ||
| Q4 24 | 3.8% | 5.2% | ||
| Q3 24 | -3.4% | 5.8% | ||
| Q2 24 | 0.4% | 6.6% | ||
| Q1 24 | -3.0% | 6.0% |
| Q4 25 | $-0.30 | $5.59 | ||
| Q3 25 | $0.48 | $5.63 | ||
| Q2 25 | $0.40 | $7.11 | ||
| Q1 25 | $-0.16 | $5.00 | ||
| Q4 24 | $0.24 | $4.88 | ||
| Q3 24 | $-0.23 | $5.33 | ||
| Q2 24 | $0.03 | $5.97 | ||
| Q1 24 | $-0.17 | $5.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $423.0M |
| Total DebtLower is stronger | $20.8B | $3.0B |
| Stockholders' EquityBook value | $-554.0M | $4.1B |
| Total Assets | $26.4B | $8.9B |
| Debt / EquityLower = less leverage | — | 0.72× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $423.0M | ||
| Q3 25 | $1.3B | $133.0M | ||
| Q2 25 | $1.7B | $106.2M | ||
| Q1 25 | $1.1B | $223.9M | ||
| Q4 24 | $1.2B | $175.7M | ||
| Q3 24 | $719.0M | $440.7M | ||
| Q2 24 | $595.0M | $134.0M | ||
| Q1 24 | $733.0M | $159.2M |
| Q4 25 | $20.8B | $3.0B | ||
| Q3 25 | $21.0B | $2.8B | ||
| Q2 25 | $21.7B | $2.9B | ||
| Q1 25 | $21.5B | $3.1B | ||
| Q4 24 | $21.6B | $3.1B | ||
| Q3 24 | $21.5B | $1.8B | ||
| Q2 24 | $21.7B | $1.5B | ||
| Q1 24 | $22.1B | $1.7B |
| Q4 25 | $-554.0M | $4.1B | ||
| Q3 25 | $-565.0M | $4.0B | ||
| Q2 25 | $-764.0M | $3.9B | ||
| Q1 25 | $-1.2B | $3.7B | ||
| Q4 24 | $-1.3B | $3.7B | ||
| Q3 24 | $-1.2B | $3.7B | ||
| Q2 24 | $-1.2B | $3.5B | ||
| Q1 24 | $-1.1B | $3.4B |
| Q4 25 | $26.4B | $8.9B | ||
| Q3 25 | $26.8B | $8.7B | ||
| Q2 25 | $27.3B | $8.6B | ||
| Q1 25 | $26.4B | $8.6B | ||
| Q4 24 | $26.5B | $8.5B | ||
| Q3 24 | $26.5B | $7.2B | ||
| Q2 24 | $26.5B | $6.8B | ||
| Q1 24 | $26.9B | $6.8B |
| Q4 25 | — | 0.72× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | — | 0.84× | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | 0.50× | ||
| Q2 24 | — | 0.44× | ||
| Q1 24 | — | 0.50× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $154.2M |
| Free Cash FlowOCF − Capex | $403.0M | $138.2M |
| FCF MarginFCF / Revenue | 14.4% | 6.2% |
| Capex IntensityCapex / Revenue | 3.3% | 0.7% |
| Cash ConversionOCF / Net Profit | — | 1.24× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $634.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $154.2M | ||
| Q3 25 | $405.0M | $171.1M | ||
| Q2 25 | $289.0M | $156.0M | ||
| Q1 25 | $211.0M | $230.3M | ||
| Q4 24 | $601.0M | $126.0M | ||
| Q3 24 | $405.0M | $34.7M | ||
| Q2 24 | $380.0M | $157.2M | ||
| Q1 24 | $211.0M | $198.3M |
| Q4 25 | $403.0M | $138.2M | ||
| Q3 25 | $314.0M | $154.1M | ||
| Q2 25 | $190.0M | $128.0M | ||
| Q1 25 | $96.0M | $214.1M | ||
| Q4 24 | $495.0M | $116.1M | ||
| Q3 24 | $334.0M | $23.2M | ||
| Q2 24 | $302.0M | $134.6M | ||
| Q1 24 | $129.0M | $186.6M |
| Q4 25 | 14.4% | 6.2% | ||
| Q3 25 | 11.7% | 6.7% | ||
| Q2 25 | 7.5% | 5.6% | ||
| Q1 25 | 4.2% | 9.9% | ||
| Q4 24 | 19.3% | 5.5% | ||
| Q3 24 | 13.3% | 1.1% | ||
| Q2 24 | 12.6% | 6.6% | ||
| Q1 24 | 6.0% | 9.6% |
| Q4 25 | 3.3% | 0.7% | ||
| Q3 25 | 3.4% | 0.7% | ||
| Q2 25 | 3.9% | 1.2% | ||
| Q1 25 | 5.1% | 0.7% | ||
| Q4 24 | 4.1% | 0.5% | ||
| Q3 24 | 2.8% | 0.6% | ||
| Q2 24 | 3.2% | 1.1% | ||
| Q1 24 | 3.8% | 0.6% |
| Q4 25 | — | 1.24× | ||
| Q3 25 | 2.26× | 1.37× | ||
| Q2 25 | 1.95× | 0.99× | ||
| Q1 25 | — | 2.06× | ||
| Q4 24 | 6.13× | 1.15× | ||
| Q3 24 | — | 0.29× | ||
| Q2 24 | 38.00× | 1.17× | ||
| Q1 24 | — | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
CACI
| Service Other | $876.3M | 39% |
| Intelligence Community | $539.0M | 24% |
| Federal Civilian Agencies | $438.6M | 20% |
| Subcontractor | $202.5M | 9% |
| Other | $148.5M | 7% |
| Commercial And Other | $15.2M | 1% |
